13-32362531-G-A

Variant summary

Our verdict is Uncertain significance.
+4 Uncertain · Hot
-7
-6
-1
0
+5
+6
+9
+10
B
LB
VUS
LP
P
The variant received 4 classification points (ACMG Germline Pathogenicity v2019). PM1PM2_SupportingPP3

The NM_000059.4(BRCA2):c.7814G>A (p.Cys2605Tyr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a cumulative frequency of 0.000000684 (AC=1) in the gnomAD database across 1,461,488 control chromosomes (no homozygotes observed). The grpmax filtering allele frequency (95% CI) is 0.0000252. In-silico predictor (REVEL) classifies this variant as likely damaging/oncogenic. Splicing prediction tools (SpliceAI) predict no significant impact on normal splicing. The affected nucleotide is highly conserved across species (PhyloP 100-way vertebrate score: 7.84). Variant has been reported in ClinVar as Uncertain Significance (★★). Other variants at the same amino acid position have been reported in ClinVar (not pathogenic): p.C2605= (synonymous): Likely_benign (ClinVar VariationId 4215244, 1 star); p.C2605R: Likely_benign (ClinVar VariationId 3261630, 1 star)

Frequency

Genomes: not found (cov: 32)
Exomes 𝑓: 6.8e-7 ( 0 hom. )

Consequence

BRCA2
NM_000059.4 missense

Scores

10
6

Clinical Significance

Uncertain significance criteria provided, multiple submitters, no conflicts U:4

Conservation

PhyloP100: 7.84

Publications

4 publications found
Variant links:
Genes affected
BRCA2 (HGNC:1101): (BRCA2 DNA repair associated) The product of this gene in involved in maintenance of genome stability. It is involved in double-strand break repair pathways during mitotic and meiotic homologous recombination and functions in protecting DNA replication forks. The encoded protein contains sites for interactions with PALB2 and EMSY and an N-terminal DNA binding domain. It also contains a RAD51 binding domain with multiple components. It has multiple BRC repeats, an alpha helix domain, oligonucleotide binding folds, and a tower-like domain. It has a nuclear localization signal and a phosphorylation site for cyclin-dependent kinase. The C-terminus of the protein can bind single-stranded and double-stranded DNA. The product of this gene interacts with multiple proteins, including RAD51. It is involved in recruiting RAD51 filaments to DNA double-strand break sites and also in cytoplasmic division. It also acts as a tumor suppressor. Mutations in this gene or decreased expression have been implicated in multiple tumor types, including breast, ovarian, pancreatic, prostate and other cancers. [provided by RefSeq, May 2026]
BRCA2 Gene-Disease associations (from GenCC):
  • BRCA2-related cancer predisposition
    Inheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
  • breast-ovarian cancer, familial, susceptibility to, 2
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp, Ambry Genetics
  • Fanconi anemia complementation group D1
    Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae), ClinGen, Ambry Genetics
  • pancreatic cancer, susceptibility to, 2
    Inheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
  • sarcoma
    Inheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
  • hereditary breast ovarian cancer syndrome
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • Fanconi anemia
    Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
  • medulloblastoma
    Inheritance: AD Classification: LIMITED Submitted by: Ambry Genetics

Genome browser will be placed here

new If you want to explore the variant's impact on the transcript NM_000059.4, check out the Mutation Effect Viewer. This is especially useful for frameshift variants or if you want to visualize the effect of exon loss / intron retention.

Classification according to ACMG Germline Pathogenicity v2019

Classification was made for transcript:

Our verdict: Uncertain_significance. The variant received 4 points.

PM1Mutational hot spot or critical domain
Missense neighbourhood hotspot (≥2 P/LP within ±8 AA, OR ≥ 5 vs. background) — PM1; In-domain: 0 pathogenic, 0 benign rare missense variants.; ±8 AA neighbourhood: 12 pathogenic, 9 benign (OR vs. background: 6.6).
PM2Absent/extremely low in population databases
Rare in gnomAD for AD/XL gene (popmax AF below threshold) — PM2 Supporting; GnomAD popmax AF = 0.0000252 — borderline rare for AD+AR gene (base 0.0001, raised to 0.000139 by highest known P/LP ClinVar AF 0.000139) — PM2 supporting.
PP3Computational evidence supports damaging effect
Germline meta computational scorer (REVEL/MetaRNN/BayesDel) predicts damaging effect — supporting evidence (PP3); Splicing verdict: not pathogenic.; Germline computational verdict: pathogenic (Supporting).

Variant Effect in Transcripts

Automated classification analysis was done for transcript: NM_000059.4. You can select a different transcript below to see updated classification assignments.

RefSeq Transcripts

BRCA2 NM_000059.4
MANE Select
HGVSc / HGVSpc.7814G>Ap.Cys2605Tyr
Exon rankExon 17 of 27
missense
Prot: NP_000050.3UniProt: A0A7P0T9D7P51587
BRCA2 NM_001432077.1
HGVSc / HGVSpc.7814G>Ap.Cys2605Tyr
Exon rankExon 17 of 27
missense
Prot: NP_001419006.1UniProt: A0A7P0T9D7P51587
BRCA2 NM_001406720.1
HGVSc / HGVSpc.7814G>Ap.Cys2605Tyr
Exon rankExon 17 of 27
missense
Prot: NP_001393649.1UniProt: A0A8V8TPZ2

Ensembl Transcripts

BRCA2 ENST00000380152.8
TSL:5MANE Select
HGVSc / HGVSpc.7814G>Ap.Cys2605Tyr
Exon rankExon 17 of 27
missense
Prot: ENSP00000369497.3UniProt: P51587
BRCA2 ENST00000544455.6
TSL:1
HGVSc / HGVSpc.7814G>Ap.Cys2605Tyr
Exon rankExon 17 of 27
missense
Prot: ENSP00000439902.1UniProt: P51587
BRCA2 ENST00000530893.7
TSL:1
HGVSc / HGVSpc.7445G>Ap.Cys2482Tyr
Exon rankExon 17 of 27
missense
Prot: ENSP00000499438.2UniProt: A0A590UJI7

Frequencies

Allele frequencies (AF), counts (AC/AN), homozygotes and coverage

Common (AF > 0.05 / Hom > 5)
Rare (AF ≤ 0.0001 / Hom ≤ 1)
Global population databases 4 sources
GnomAD3 genomes
Cov:32
GnomAD2 exomes
AF: 0.00000398
AC:1
AN:251066
GnomAD4 exome
AF: 6.84e-7
AC:1
Hom:0
AN:1461488
Cov:33
GnomAD4 genome
Cov:32
Local & regional cohorts 1 source
Korea4K (4,157 Koreans)
AF: 0.000276
AC:2
AN:7234
Showing 5 sources

ClinVar

ClinVar submissions
Significance:Uncertain significance
Revision:criteria provided, multiple submitters, no conflicts
View on ClinVar
Pathogenic
VUS
Benign
Condition
-
2
-
Hereditary cancer-predisposing syndrome (2)
-
1
-
Familial colorectal cancer type X (1)
-
1
-
Hereditary breast ovarian cancer syndrome (1)

Computational Scores

AlphaGenome AVI
Pathogenic25
AlphaMissense
Uncertain0.55
BayesDel_addAF
Pathogenic0.29D
BayesDel_noAF
Pathogenic0.18
CADD
Pathogenic27
DANN
Uncertain1.0
Eigen
Pathogenic0.92
Eigen_PC
Pathogenic0.89
FATHMM_MKL
Pathogenic0.99D
FuncVEP CTI
Pathogenic0.58
GPN-Star LLR
N/A-9.5
GPN-Star score
N/A9.5
M_CAP
Uncertain0.23D
MetaRNN
Pathogenic0.85D
MetaSVM
Uncertain0.72D
Mutation Taster
N/A28/72disease causing
PhyloP100
Pathogenic7.8
PrimateAI
Pathogenic0.86D
PROVEAN
Uncertain-2.9D
REVEL
Pathogenic0.74
Sift
Pathogenic0.0D
Sift4G
Uncertain0.0050D
VESM-3B
Benign-7.7
Showing 23 of 23 scores

Splicing Scores

Pangolin (max)
Benign0.0
SpliceAI score (max)
Benign0.010
Details are displayed if max score is > 0.2
Showing 2 of 2 scores

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

MaxEntScan Visualizer can be used to analyze the impact of this mutation on the neighboring sequence.

MaveDB functional evidence

MaveDB is a public repository of laboratory assays that test the effect of thousands of variants at once — treat this as supporting research data and interpret it with great caution; it is not a clinical classification.

1 normal (RUO)
1 no calibration
Nucleotide level
Scores from sGE of BRCA2 exons 15–26 in humanized mouse embryonic stem cells
SGE of BRCA2 exons 15–26 in humanized mouse embryonic stem cells
Gene
BRCA2
Score
-0.442
Classified as
No clinical calibration. Only research-use-only (RUO) calibrations exist for this assay — they are not reliable evidence; treat them with extreme caution.
BS3 moderateFunctionally normalRUO
ExCALIBR calibration (ClinVar 2018): BS3 Moderate (-2)
+1 more calibration
BS3 supportingFunctionally normalRUO
ExCALIBR calibration: BS3 Supporting (-1)
Nucleotide level
Scores from sGE of BRCA2 exons 15 to 26 in Hap1 cells
SGE of BRCA2 exons 15 to 26 in Hap1 cells
Gene
BRCA2
Score
-0.0845
No calibration data
This score is at approximately the 23th percentile of all variants tested in this assay.
This score has not been calibrated against ACMG evidence — shown for context only, not as clinical evidence.

Publications

Other links and lift over

For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.